missing translation for 'onlineSavingsMsg'
Få mere at vide
Få mere at vide
Clemastine Fumarate, Mikromol™
Beskrivelse
Clemastine Fumarate
Tekniske data
Tekniske data
| Kemisk navn eller materiale | Clemastine Fumarate |
| CAS | 14976-57-9 |
| Analyt- eller komponentnavne | Clemastine Fumarate |
| Forsendelsestilstand | Room Temperature |
| Molekylær formel | C21 H26 Cl N O . C4 H4 O4 |
| Certificeringer/compliance | ISO 17025 |
| Synonym | Clemastine fumarate, (2R)-2-[2-[(R)-1-(4-Chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine (E)-butenedioate, Pyrrolidine, 2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methyl-, (2R)-, (2E)-2-butenedioate (1:1), Clemastine Fumarate, Pyrrolidine, 2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methyl-, [R-(R*,R*)]-, (E)-2-butenedioate (1:1), Agasten, Aloginan, Alphamin, Anhistan, Bravegyl, Clemastine hydrogen fumarate, Fuluminol, HS 592, Inbestan, Kinotomin, Lacretin, Lecasol, Maikohis, Mallermin F, Marsthine, Masletine, Meclastine fumarate, Mecloprodine, Piloral, Reconin, Tavegil, Tavegyl, Tavist, Telgin, Telgin G, Trabest, Xolamin, Pyrrolidine, 2-[2-[(p-chloro-alpha-methyl-alpha-phenylbenzyl)oxy]ethyl]-1-methyl-, (+)-, fumarate (1:1) (8CI), (+)-2-[2-[(p-Chloro-alpha-methyl-alpha-phenylbenzyl)oxy]ethyl]-1-methylpyrrolidine fumarate |
| InChI formel | InChI=1S/C21H26ClNO.C4H4O4/c1-21(17-7-4-3-5-8-17,18-10-12-19(22)13-11-18)24-16-14-20-9-6-15-23(20)2;5-3(6)1-2-4(7)8/h3-5,7-8,10-13,20H,6,9,14-16H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t20-,21-;/m1./s1 |
| SMIL | CN1CCC[C@@H]1CCO[C@](C)(c2ccccc2)c3ccc(Cl)cc3.OC(=O)\C=C\C(=O)O |
| IUPAC navn | (E)-but-2-enedioic acid;(2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine |
| Vis mere |
Produkttitel
Ved at klikke på Send, anerkender du, at du kan blive kontaktet af Fisher Scientific med hensyn til den feedback, du har givet i denne formular. Vi deler ikke dine oplysninger til andre formål. Alle angivne kontaktoplysninger skal også vedligeholdes i overensstemmelse med vores Privatlivspolitik.
Ser du en mulighed for forbedring?